Search

Your search keyword '"S. Seldrum"' showing total 16 results
Start Over Author "S. Seldrum" Search Limiters Full Text
16 results on '"S. Seldrum"'

1. Impact on survival of the severity in aortic stenosis in initially non operated patients

Author

Antoine Guedes, E. Schröder, K. Marcovitch, S. Seldrum, M. Buche, Benoît Bihin, M. Gérard, Vincent Dangoisse, C. Hanet, L. Gabriel, and B. Marchandise

Subjects
Stenosis, medicine.medical_specialty, business.industry, Medicine, Radiology, macromolecular substances, Cardiology and Cardiovascular Medicine, business, medicine.disease, Surgery
Abstract

Background The national history of mild/moderate aortic stenosis (AS) has been previously reported in 3 studies. Aim We sought to assess the impact of the severity of AS in a group of patients initially managed medically. Methods A consecutive group of 399 patients with AS as assessed in our echolab (6.2.2002‐22.7.2003). Patients with a previous aortic prosthesis or operated within 3 months after diagnosis of AS were excluded. Patients were classified according to AS severity: * mild AS (AV area > 1.5‐2 cm2) * moderate AS (AV area 1‐1.5 cm2) * severe AS (AV area 0.8‐0.99 cm2) * very severe AS (AV area 0.8 cm2 had no impact on survival. The relative impact of the AS severity in addition to the clinical parameters (log Euroscore, age, NYHA, LVEJF) was assessed by the ROC model. The predictive performance was only slightly improved (by 2 ‐ 3%) by including the AS severity. Conclusion Survival in patients with very severe AS is reduced in comparison to patients with less severe AS. Survival in patients with less severe AS (AV area > 0.8 cm2) depends mainly on clinical characteristics, but not on degree of AS severity. There seems to be a place for randomized trials on the management of patients with less severe AS (AV area: 0.8‐1 cm2).

Published
2017
Full Text
View/download PDF

2. Poster session Thursday 6 December - AM: Other myocardial diseases

Author

Z. Ojaghi-Haghighi, A. Mostafavi, H. Moladoust, F. Noohi, M. Maleki, M. Esmaeilzadeh, N. Samiei, S. Hosseini, R. Jasaityte, A. Teske, P. Claus, B. Verheyden, F. Rademakers, J. D'hooge, A. Patrianakos, A. Zacharaki, A. Kalogerakis, E. Nyktari, P. Maniatakis, F. Parthenakis, P. Vardas, J. M. Hilde, I. Skjoerten, S. Humerfelt, V. Hansteen, M. Melsom, J. Hisdal, K. Steine, R. Ippolito, P. Gripari, D. Muraru, R. Esposito, G. Kocabay, G. Tamborini, M. Galderisi, F. Maffessanti, L. Badano, M. Pepi, S. Yurdakul, F. Oner, T. Sahin, B. Avci, Y. Tayyareci, H. Direskeneli, S. Aytekin, T. Filali, B. Jedaida, D. Lahidheb, M. Gommidh, H. Mahfoudhi, N. Hajlaoui, R. Dahmani, W. Fehri, H. Haouala, V. Andova, L. Georgievska-Ismail, E. Srbinovska-Kostovska, Y. Gardinger, J. Joanna Hlebowicz, O. Ola Bjorgell, M. Magnus Dencker, M.-T. Liao, C.-T. Tsai, J.-L. Lin, K. Piestrzeniewicz, K. Luczak, M. Maciejewski, J. Komorowski, J. Jankiewicz-Wika, J. Drozdz, M. F. Ismail, A. Alasfar, M. Elassal, S. El-Sayed, M. Ibraheim, P. Dobrowolski, A. Klisiewicz, E. Florczak, A. Prejbisz, E. Szwench, J. Rybicka, A. Januszewicz, P. Hoffman, M. Santos Furtado, K. Nogueira, A. Arruda, A. C. Rodrigues, F. Carvalho, M. Silva, A. Cardoso, E. Lira-Filho, J. Pinheiro, J. L. Andrade, M. Mohammed, C. Zito, M. Cusma-Piccione, G. Di Bella, N. Taha, D. Zagari, A. Oteri, A. Quattrone, I. Boretti, S. Carerj, O. Obremska, B. Boratynska, P. Poczatek, Z. Zon, M. Magott, K. Klinger, O. Szenczi, Z. Szelid, P. Soos, Z. Bagyura, E. Edes, P. Jozan, B. Merkely, J. Ahn, D. Kim, D. Jeon, I. Kim, F. Baeza Garzon, M. Delgado, D. Mesa, M. Ruiz, J. S. De Lezo, M. Pan, C. Leon, F. Castillo, M. Morenate, F. Toledano, L. Zhong, E. Lim, N. Shanmugam, S. Law, B. Ong, K. Katwadi, R. Tan, Y. Chua, R. Liew, Z. Ding, H. Von Bibra, C. Leclerque, T. Schuster, P.-M. Schumm-Draeger, M. Bonios, A. Kaladaridou, O. Papadopoulou, A. Tasoulis, C. Pamboucas, A. Ntalianis, J. Nanas, S. Toumanidis, D. Silva, N. Cortez-Dias, P. Carrilho-Ferreira, R. Placido, C. Jorge, C. Calisto, S. Robalo Martins, J. Carvalho De Sousa, F. Pinto, A. Nunes Diogo, M. Przewlocka-Kosmala, A. Orda, B. Karolko, A. Mysiak, W. Kosmala, S. Moral Torres, J. Rodriguez-Palomares, V. Pineda, D. Gruosso, A. Evangelista, D. Garcia-Dorado, J. Figueras, E. Cambronero, M. J. Corbi, A. Valle, J. Cordoba, C. Llanos, M. Fernandez, I. Lopez, V. Hidalgo, M. Barambio, J. Jimenez, A. D'andrea, L. Riegler, R. Cocchia, M. Russo, E. Bossone, R. Calabro, A. Iniesta Manjavacas, S. Valbuena Lopez, T. Lopez Fernandez, S. Garcia-Blas, F. De Torres Alba, J. G. De Diego, U. Ramirez Valdiris, J. Mesa Garcia, M. Moreno Yanguela, J. Lopez-Sendon, B. Logstrup, H. Andersen, L. Thuesen, E. Christiansen, K. Terp, K. Klaaborg, S. Poulsen, A. Cacicedo, S. Velasco, U. Aguirre, J. Onaindia, I. Rodriguez, G. Oria, A. Subinas, G. Zugazabeitia, A. Romero, E. Laraudogoitia Zaldumbide, S. Weisz, J. Magne, R. Dulgheru, M. Rosca, L. Pierard, P. Lancellotti, V. Auffret, E. Donal, M. Bedossa, D. Boulmier, M. Laurent, J. Verhoye, H. Le Breton, S. Van Hall, T. Herbrand, U. Ketterer, S. Keymel, Y. Boering, T. Rassaf, C. Meyer, T. Zeus, M. Kelm, J. Balzer, M. Floria, S. Seldrum, M. Mariciuc, G. Laurence, M. Buche, P. Eucher, Y. Louagie, J. Jamart, B. Marchandise, E. Schroeder, A. Venkatesh, A. Sahlen, J. Johnson, L. Brodin, R. Winter, K. Shahgaldi, A. Manouras, L. Fusini, M. Muratori, F. Alamanni, A. Bartorelli, C. Ferrari, E. Caiani, E. Yaroslavskaya, V. Kuznetsov, G. Pushkarev, D. Krinochkin, I. Zyrianov, C. Ciobotaru, Y. Kobayashi, K. Yamamoto, E. Hirose, A. Hirohata, T. Ohe, P. Jhund, T. Cunningham, V. Murday, I. Findlay, P. Sonecki, I. Rangel, C. Sousa, A. Goncalves, A. Correia, A. Vigario, E. Martins, J. Silva-Cardoso, F. Macedo, M. Maciel, D. Lovric, J. Samardzic, D. Milicic, V. Reskovic, Z. Baricevic, I. Ivanac, J. Separovic Hanzevacki, K. Kim, J. Song, H. Jeong, H. Yoon, Y. Ahn, M. Jeong, J. Cho, J. Park, J. Kang, A. Iorio, B. Pinamonti, M. Bobbo, M. Merlo, G. Barbati, L. Massa, G. Faganello, A. Di Lenarda, G. Sinagra, F. Heggemann, K. Hamm, F. Streitner, T. Sueselbeck, T. Papavassiliu, M. Borggrefe, D. Haghi, F. Ferreira, A. Galrinho, R. Soares, L. Branco, J. Abreu, J. Feliciano, A. Papoila, M. Alves, A. Leal, R. Ferreira, A. Reynaud, L. H. Lund, E. Oger, E. Drouet, C. Hage, F. Bauer, C. Linde, J. Daubert, F. Schnell, P. Lentz, G. Kervio, G. Leurent, P. Mabo, F. Carre, A. Rodrigues, M. Roque, D. Becker, S. Barros, F. Kay, T. Emerick, P. Sampaio-Barros, J. Andrade, S. Yamada, K. Okada, H. Iwano, H. Nishino, M. Nakabachi, S. Yokoyama, S. Kaga, T. Mikami, H. Tsutsui, R. Mincu, S. Magda, S. Dumitrache Rujinski, T. Constantinescu, S. Mihaila, A. Ciobanu, M. Florescu, D. Vinereanu, T. Ashcheulova, O. Kovalyova, E. Ardeleanu, D. Gurgus, A. Gruici, R. Suciu, I. Ana, L. Bergenzaun, H. Ohlin, P. Gudmundsson, R. Willenheimer, M. Chew, A. Charalampopoulos, L. Howard, R. Davies, W. Gin-Sing, I. Tzoulaki, I. Grapsa, S. Gibbs, P. Massabuau, L. Weinert, O. Lairez, M. Berry, M. Sotaquira, P. Vaida, R. Lang, I. Khan, D. Waterhouse, S. Asegdom, M. Alqaseer, D. Foley, B. Mcadam, P. Colonna, E. Michelotto, W. Genco, M. Rubino, S. Pugliese, A. Belfiore, M. Sorino, M. Trisorio Liuzzi, G. Antonelli, G. Palasciano, A. Duszanska, I. Skoczylas, W. Streb, T. Kukulski, L. Polonski, Z. Kalarus, A. Fleig, K. Seitz, S. Secades, M. Martin, C. Corros, M. Rodriguez, J. De La Hera, A. Garcia, E. Velasco, E. Fernandez, V. Barriales, J. Lambert, D. R. Zwas, S. Hoss, D. Leibowitz, R. Beeri, C. Lotan, D. Gilon, K. Wierzbowska-Drabik, N. Roszczyk, M. Sobczak, M. Plewka, L. Chrzanowski, P. Lipiec, J. Kasprzak, K. Wita, K. Mizia-Stec, W. Wrobel, E. Plonska-Gosciniak, T. Pinho, Y. Wang, H. Houle, A. J. Madureira, J. Zamorano, M. J. Maciel, R. Ancona, S. Comenale Pinto, P. Caso, M. Coppola, O. Rapisarda, R. Calabro', R. Cadenas Chamorro, T. Lopez, J. Gomez, M. Moreno, P. Salinas, C. Jimenez Rubio, S. Valbuena, A. Manjavacas, F. De Torres, T. Vaugrenard, O. Huttin, A. Rouge, J. Schwartz, P. Zinzius, B. Popovic, J. Sellal, E. Aliot, Y. Juilliere, C. Selton-Suty, J. Looi, A. Lee, M. Hsiung, W. Song, R. Wong, M. J. Underwood, F. Fang, Q. Lin, Y. Lam, C. Yu, A. Vitarelli, B. Nguyen, L. Capotosto, G. D-Alessandro, M. D-Ascanio, A. Rafique, E. Gang, F. Barilla, R. Siegel, A. Kydd, F. Khan, W. Watson, L. Mccormick, M. Virdee, D. Dutka, S. Ranjbar, M. Karvandi, S. Hassantash, J. Grapsa, I. Efthimiadis, T. Pakrashi, D. Dawson, P. Punjabi, P. Nihoyannopoulos, M. Henein, S. Soderberg, E. Tossavainen, P. Lindqvist, H. Bellsham-Revell, A. Bell, O. Miller, J. Simpson, E. Altekin, M. Kucuk, A. Yanikoglu, S. Karakas, A. Er, D. Ozel, C. Ermis, I. Demir, G. Bajraktari, G. Di Salvo, L. Baldini, F. Del Gaizo, A. Rea, V. Pergola, G. Pacileo, B. Fadel, J.-S. Seo, G.-N. Choi, H.-Y. Jin, S.-H. Seol, J.-S. Jang, T.-H. Yang, D.-K. Kim, D.-S. Kim, E. Papadopoulou, S. Hatzidou, J. Agrios, C. Pamboukas, A. Antoniou, P. Gargiulo, S. Dellegrottaglie, D. Bruzzese, O. Scala, C. D'amore, D. Ruggiero, C. Marciano, E. Vassallo, E. Pirozzi, P. Perrone Filardi, V. Mor-Avi, N. Kachenoura, J. Lodato, S. Port, S. Chandra, B. Freed, N. Bhave, B. Newby, A. Patel, G. Dwivedi, M. Alam, K. Boczar, B. Chow, G. Staskiewicz, E. Czekajska-Chehab, S. Uhlig, A. Tomaszewski, J. Przegalinski, R. Maciejewski, A. Drop, G. Di Giammarco, C. Canosa, M. Foschi, G. Liberti, M. Bedir, D. Marinelli, S. Masuyama, R. Rabozzi, S. Vijayan, H. Miller, R. Muthusamy, S. Smith, L. Gargani, P. Pang, E. Davis, A. Schumacher, R. Sicari, E. Picano, A. Chmiel, M. Mizia, M. Haberka, K. Gieszczyk, A. Sikora - Puz, B. Lasota, O. Trojnarska, S. Grajek, Z. Gasior, A. Koumoulidis, I. Vlasseros, D. Tousoulis, V. Katsi, A. Avgeropoulou, M. Divani, C. Stefanadis, and I. Kallikazaros

Subjects
medicine.medical_specialty, business.industry, Internal medicine, Cardiology, medicine, Radiology, Nuclear Medicine and imaging, General Medicine, Function (mathematics), Cardiology and Cardiovascular Medicine, Independent predictor, business, Ventricular geometry
Published
2012
Full Text
View/download PDF

3. Poster Session: Right ventricular systolic function

Author

M. Altman, C. Bergerot, H. Thibault, A. Aussoleil, E. Skuldadt Davidsen, M. Barthelet, G. A. Derumeaux, J. Grapsa, I. Zimbarra Cabrita, J. Afilalo, S. Paschou, D. Dawson, G. Durighel, D. O'regan, L. Howard, J. Gibbs, P. Nihoyannopoulos, M. Morenate Navio, M. Mesa Rubio, M. D. Ortega, M. Ruiz Ortiz, F. Castillo Bernal, C. L. Del Pino, F. Toledano, M. P. Alvarez-Ossorio, S. Ojeda Pineda, J. S. D. Lezo Cruz-Conde, R. Jasaityte, P. Claus, A. Teske, L. Herbots, B. Verheyden, F. Rademakers, J. D'hooge, C. G. Tocchetti, C. Coppola, D. Rea, C. Quintavalle, L. Guarino, N. Castaldo, C. De Lorenzo, G. Condorelli, C. Arra, N. Maurea, D. Voilliot, O. Huttin, Y. Camara, W. Djaballah, S. Carillo, P. Zinzius, J. Sellal, M. Angioi, Y. Juilliere, C. Selton-Suty, P. Dobrowolski, A. Klisiewicz, E. Florczak, A. Prejbisz, E. Szwench, J. Rybicka, A. Januszewicz, P. Hoffman, A. Jurado Roman, S. De Dios Perez, J. M. M. De Nicolas, B. Diaz Anton, B. Rubio Alonso, R. Martin Asenjo, S. Mayordomo Gomez, L. Villagraz Tecedor, L. Blazquez, R. T. De Meneses, A. Bernard, A. I. Hernandez, A. Reynaud, C. Lerclercq, J. Daubert, E. Donal, R. Arjan Singh, S. Sivarani, S. Lim, W. Azman, M. Almeida, N. Cardim, V. Fonseca, V. Carmelo, S. Santos, T. Santos, J. Toste, W. Kosmala, A. Orda, B. Karolko, A. Mysiak, M. Przewlocka-Kosmala, K. Farsalinos, D. Tsiapras, S. Kyrzopoulos, E. Avramidou, D. Vassilopoulou, V. Voudris, H. Hayrapetyan, K. Adamyan, J. Montero Cabezas, C. Granda Nistal, B. Garcia Aranda, V. Sanchez Sanchez, A. Sestito, P. Lamendola, A. Di Franco, C. Lauria, G. Lanza, M. Kukucka, A. Unbehaun, S. Buz, A. Mladenow, H. Kuppe, M. Pasic, H. Habazettl, D. Gemma, N. Montoro Lopez, M. G. R. De Celix, T. Lopez Fernandez, F. De Torres Alba, D. I. Del Valle, U. Ramirez, J. Mesa, M. Moreno Yanguela, J. Lopez Sendon, G. W. Eveborn, H. Schirmer, P. Lunde, G. Heggelund, K. Rasmussen, Z. Wang, B. Lasota, K. Mizia-Stec, M. Mizia, A. Chmiel, T. Adamczyk, J. Chudek, Z. Gasior, A. Venkatesh, J. Johnson, A. Sahlen, L. Brodin, R. Winter, K. Shahgaldi, A. Manouras, S. Valbuena, A. Iniesta, T. Lopez, F. De Torres, P. Salinas, S. Garcia, M. Moreno, J. Lopez-Sendon, I. Lebid, T. Kobets, T. Kuzmenko, S. Katsanos, K. Yiu, M. Clavel, N. Nina Ajmone, F. Van Der Kley, J. Rodes Cabau, M. Schalij, J. Bax, P. Pibarot, V. Delgado, L. Fusini, G. Tamborini, M. Muratori, P. Gripari, N. Marsan, C. Cefalu', S. Ewe, F. Maffessanti, M. Pepi, N. Hasselberg, K. Haugaa, H. Petri, K. Berge, T. Leren, H. Bundgaard, T. Edvardsen, R. Ancona, S. Comenale Pinto, P. Caso, M. Coppola, O. Rapisarda, C. Cavallaro, F. Vecchione, A. D'onofrio, R. Calabro', R. Rimbas, S. Mihaila, O. Enescu, N. Patrascu, R. Dragoi, M. Rimbas, C. Pop, D. Vinereanu, S. Gustafsson, S. Morner, C. Gronlund, O. Suhr, P. Lindqvist, G. Di Bella, C. Zito, F. Minutoli, A. Madaffari, M. Cusma Piccione, A. Mazzeo, R. Massimo, M. Pasquale, G. Vita, S. Carerj, I. Rangel, A. Goncalves, C. Sousa, A. Correia, E. Martins, J. Silva-Cardoso, F. Macedo, M. Maciel, B. Pfeiffer, A. Rigopoulos, H. Seggewiss, M. Alvarez Fuente, T. Sainz Costa, C. Medrano, M. Navarro, D. Blazquez Gamero, J. Ramos, M. Mellado, M. De Jose, M. Munoz, E. Maroto, L. Gargani, P. Gosciniak, L. Pratali, G. Agoston, C. Bruni, S. Guiducci, M. Matucci Cerinic, A. Varga, R. Sicari, E. Picano, C. Zhao, M. Mei, C. Yeung, C. Siu, H. Tse, M. Florescu, L. Magda, R. Mincu, I. Daha, C. M. Stanescu, L. Chirila, C. Baicus, A. Vlase, G. Dan, M. Montoro Lopez, R. Florez Gomez, A. Alonso Ladreda, C. Itziar Soto, J. Rios Blanco, G. Guzman Martinez, B. Lichodziejewska, K. Kurnicka, S. Goliszek, M. Kostrubiec, O. Dzikowska-Diduch, M. Ciurzynski, A. Labyk, M. Krupa, P. Palczewski, P. Pruszczyk, C. C. De Sousa, A. Vigario, T. Pinho, J. Silva Cardoso, S.-J. Park, J.-E. Song, Y.-J. Lee, M.-R. Ha, S.-A. Chang, J.-O. Choi, S.-C. Lee, S. Park, J. Oh, A. Van De Bruaene, P. De Meester, R. Buys, L. Vanhees, M. Delcroix, J. Voigt, W. Budts, A. Blundo, S. Buccheri, I. P. Monte, S. Leggio, C. Tamburino, M. Sotaquira, R. Lang, E. Caiani, M. Floria, L. De Roy, O. Xhaet, D. Blommaert, J. Jamart, M. Gerard, O. Deceuninck, B. Marchandise, S. Seldrum, E. Schroeder, B. Unsworth, S. Sohaib, K. Kulwant-Kaur, L. Malcolme-Lawes, P. Kanagaratnam, I. Malik, B. Ren, H. Mulder, A. Haak, M. Van Stralen, T. Szili-Torok, J. Pluim, M. Geleijnse, J. Bosch, R. Baglini, A. Amaducci, G. D'ancona, S. Van Den Oord, Z. Akkus, G. Ten Kate, G. Renaud, E. Sijbrands, N. De Jong, A. Van Der Lugt, A. Van Der Steen, A. Schinkel, A. Bjallmark, M. Larsson, D. Grishenkov, L.-A. Brodin, T. Brismar, G. Paradossi, K. A. Sveen, T. Nerdrum, K. Hanssen, K. Dahl-Jorgensen, K. Steine, S. Cimino, G. Pedrizzetti, G. Tonti, E. Canali, V. Petronilli, F. Cicogna, L. Arcari, L. De Luca, C. Iacoboni, L. Agati, S. S. Abdel Moneim, S. Eifert Rain, M. Bernier, G. Bhat, M. Hagen, D. Bott-Kitslaar, R. Castello, S. Wilansky, P. Pellikka, S. Mulvagh, I. Delithanasis, J. Celutkiene, C. Kenny, M. Monaghan, W. Park, G. Hong, J. Son, S. Lee, U. Kim, J. Park, D. Shin, Y. Kim, K. Toutouzas, M. Drakopoulou, C. Aggeli, I. Felekos, C. Nikolaou, A. Synetos, K. Stathogiannis, E. Tsiamis, E. Siores, C. Stefanadis, B. Plicht, P. Kahlert, T. Grave, T. Buck, T. Konorza, M. Gursoy, T. Gokdeniz, M. Astarcioglu, Z. Bayram, B. Cakal, S. Karakoyun, M. Kalcik, R. Acar, G. Kahveci, M. Ozkan, W. Tsang, L. Weinert, S. Yurdakul, B. Avci, S. Sahin, B. Dilekci, S. Aytekin, F. Arenga, S. Hascoet, R. Martin, Y. Dulac, M. Peyre, C. Benzouid, K. Hadeed, P. Acar, D. Zakarkaite, V. Skorniakov, V. Zvironaite, V. Grabauskiene, J. Burca, L. Ciparyte, A. Laucevicius, G. Di Salvo, A. Rea, A. D'aiello, F. Del Gaizo, V. Pergola, A. D'andrea, G. Pacileo, R. Calabro, M. Russo, C. Dedobbeleer, A. Hadefi, R. Naeije, P. Unger, C. Mornos, D. Cozma, A. Ionac, A. Mornos, M. Valcovici, S. Pescariu, L. Petrescu, K. Hu, D. Liu, M. Niemann, S. Herrmann, M. Cikes, S. Stoerk, S. Knop, G. Ertl, B. Bijnens, F. Weidemann, M. De Knegt, T. Biering-Sorensen, P. Sogaard, J. Sivertsen, J. Jensen, R. Mogelvang, W. Lam, M. Tang, K. Chan, Y. Yang, F. Fang, J. Sun, C. Yu, Y. Lam, V. Panoulas, S. Sulemane, A. Bratsas, K. Konstantinou, M. Francone, T. Schau, M. Seifert, D. Ridjab, M. Schoep, M. Gottwald, M. Neuss, J. Meyhoefer, M. Zaenker, C. Butter, A. Tarr, S. Stoebe, D. Pfeiffer, A. Hagendorff, E. Maret, B.-M. Ahlander, P.-G. Bjorklund, J. Engvall, G. Staskiewicz, E. Czekajska-Chehab, P. Adamczyk, E. Siek, P. Przybylski, R. Maciejewski, A. Drop, C. Jimenez Rubio, G. Isasti Aizpurua, J. Miralles Ibarra, M. Al-Mallah, T. Somg, S. Alam, J. Chattahi, B. Zweig, K. Dhanalakota, S. Boedeker, K. Ananthasubramaniam, C. Park, K. March, S. Jones, J. Mayet, T. Tillin, N. Chaturvedi, A. Hughes, E. Hamodraka, E. Kallistratos, A. Karamanou, T. Tsoukas, D. Mavropoulos, N. Kouremenos, I. Zaharopoulou, N. Nikolaidis, D. Kremastinos, A. Manolis, M. Loboz-Rudnicka, J. Jaroch, Z. Bociaga, E. Kruszynska, B. Ciecierzynska, M. Dziuba, K. Dudek, I. Uchmanowicz, K. Loboz-Grudzien, D. Silva, A. Magalhaes, C. Jorge, N. Cortez-Dias, P. Carrilho-Ferreira, J. Silva Marques, I. Portela, C. Pascoa, A. Nunes Diogo, D. Brito, B. Roosens, G. Bala, S. Droogmans, J. Hostens, J. Somja, E. Delvenne, J. Schiettecatte, T. Lahoutte, G. Van Camp, and B. Cosyns

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, Cardiology, Radiology, Nuclear Medicine and imaging, General Medicine, Session (computer science), Systolic function, Cardiology and Cardiovascular Medicine, business
Published
2012
Full Text
View/download PDF

4. Natural history of the enlarged ascending thoracic aorta

Author

Antoine Guedes, P. Eucher, S. Seldrum, L. Gabriel, Benoît Bihin, E. Schröder, M. Buche, B. Marchandise, M. Floria, C. Hanet, M. Gérard, and J. Felix

Subjects
medicine.medical_specialty, business.industry, Incidence (epidemiology), Retrospective cohort study, Group B, Surgery, Natural history, Long term learning, medicine.artery, Medicine, Thoracic aorta, Observational study, Cumulative incidence, Cardiology and Cardiovascular Medicine, business
Abstract

To assess the long-term outcome of patients with an enlarged ascending thoracic aorta (ATA), a retrospective study was performed. Methods Inclusion criteria: ATA diameter of 38 mm or more by ETT (813 consecutive cases). Inclusion period: 01.1.2003–31.12.2016. Results At baseline, the mean diameter of the ATA was 42 ± 3 mm, the mean Z-score was 2.7 ± 0.8. Six years later, the mean diameter was 41.9 ± 4.8 mm, the mean Z-score 2.4 ± 1.1. During the follow-up, 52 patients had an intervention on the ATA, 22 patients were operated within the first 3 months after the diagnostic echocardiogram. In the 791 remaining patients (without early intervention), the event rate (death, intervention on the ATA) was assessed by the competing risk model. In the group of patients with a baseline ATA diameter of less than 41 mm (Group A: n = 254), the cumulative incidence of death at 5 and 10 y was 34% and 61%; in the group of patients with an ATA diameter of 41–42 mm (Group B: n = 238) the incidence was 34% and 61% respectively, in the group of patients with an ATA diameter of 43-44 mm (Group C: n = 147), the incidence was 32% and 58%, in the group of patients with a diameter of 45 and more (Group D: n = 150), the incidence was 31.1% and 61% (NS). The cumulative incidence of intervention at 5 and 10 years was 0.4% and 1% in group A, 1.3 and 1.8% in group B, 0.7 and 1.4% in group C and 9.8 and 12.9% in group D (P 3, the incidence of intervention at 5 and 10 y was respectively 7.6% and 10.7% (P = 0.01). Conclusions The diameter of the enlarged ATA remained nearly unchanged over a period of 6 years. No impact of the enlarged ATA on survival was observed. Only patients with an ATA diameter of 45 mm and more (or a Z-score of 3 and more) needed an intervention at a rate of ±10% at 10 y after the initial echocardiographic diagnosis.

Published
2018
Full Text
View/download PDF

5. Determinants of long-term outcome in patients with mild/moderate aortic valve stenosis

Author

L. Gabriel, V. Gerard, C. Hanet, Benoît Bihin, E. Schröder, C. Tasiaux, K. Marcovitch, Patrick Chenu, Antoine Guedes, B. Marchandise, M. Floria, Vincent Dangoisse, S. Seldrum, and D. Blommaert

Subjects
medicine.medical_specialty, business.industry, Proportional hazards model, Hemodynamics, EuroSCORE, medicine.disease, Stenosis, Aortic valve replacement, Aortic valve stenosis, Heart failure, Internal medicine, Cohort, medicine, Cardiology, Cardiology and Cardiovascular Medicine, business
Abstract

Background Previous studies on the natural history of mild/moderate aortic valve stenosis used the combined end-point of death and aortic valve replacement (AVR). Aim The aim of our study was to assess the very long-term outcome (survival) of patients with mild/moderate aortic stenosis (AS). Methods A consecutive series of 760 patients with the diagnosis of mild (AVA > 1.5 cm2–2 cm2, n = 408) and of moderate (AVR > 1 cm2–1.5 cm2, n = 352) AS during the inclusion period from 01.12.2003 to 01.05.2006 were followed. Follow-up duration ≥ 10 years in all patients. Vital status (national vital statistics) was assessed on 29.10.2016. Completeness of follow-up: 100%. Mean age: 76 ± 10 y. Logistic Euroscore: 13 ± 11; Euroscore 2010: 4.3 ± 4.9. Results Overall survival at 1–5–10 years according to AS severity was respectively for mild AS: 88%–60%–39% and for moderate AS: 85%–54%–30%. The following baseline characteristics were independently (COX model) associated with poor outcome (death following follow-up) ( Table 1 ). The severity of AS was not found to be an independent prediction of poor survival (death). Moreover the median (50%) time to AVR was 9 y. in case of moderate AS and 12 y. in case of mild AS. Conclusion In this large patients cohort (760 pts) with mild/moderate AS, the very long-term outcome (> 10 y) was depending on clinical and hemodynamic variables such as age, comorbidities, LV dysfunction, signs of heart failure and renal failure, but not on the AS severity. The severity of AS seems not to have an independent impact on overall survival.

Published
2018
Full Text
View/download PDF

6. Quality control assessment in cardiac surgery

Author

M. Buche, Y. Louagie, Antoine Guedes, C. Hanet, Vincent Dangoisse, Benoît Bihin, I. Michaux, L. Guillaume, P. Eucher, M. Gérard, E. Schröder, L. Gabriel, S. Seldrum, and A. Dive

Subjects
medicine.medical_specialty, business.industry, media_common.quotation_subject, medicine.medical_treatment, medicine.disease, Single Center, Prosthesis, Surgery, Cardiac surgery, Aortic valve replacement, Internal medicine, medicine, Cardiology, Quality (business), Cardiology and Cardiovascular Medicine, business, media_common
Published
2017
Full Text
View/download PDF

7. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial.

Author

Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho GY, Popescu BA, Kosmala W, Costello B, la Gerche A, Mottram P, Thomas L, Seldrum S, Hristova K, Bansal M, Kurosawa K, Fukuda N, Yamada H, Izumo M, Tajiri K, Sinski M, Vinereanu D, Shkolnik E, Banchs J, Kutty S, Negishi K, and Marwick TH

Subjects
Humans, Female, Adult, Middle Aged, Aged, Male, Prospective Studies, Predictive Value of Tests, Ventricular Function, Left, Antibiotics, Antineoplastic adverse effects, Cardiotoxicity drug therapy, Anthracyclines adverse effects, Stroke Volume, Ventricular Dysfunction, Left chemically induced, Ventricular Dysfunction, Left diagnostic imaging, Breast Neoplasms drug therapy, Heart Diseases chemically induced, Heart Failure chemically induced, Heart Failure diagnostic imaging, Heart Failure drug therapy
Abstract

Background: Global longitudinal strain (GLS) can predict cancer therapeutics-related cardiac dysfunction and guide initiation of cardioprotection (CPT)., Objectives: In this study, the authors sought to determine whether echocardiography GLS-guided CPT provides less cardiac dysfunction in survivors of potentially cardiotoxic chemotherapy, compared with usual care at 3 years., Methods: In this international multicenter prospective randomized controlled trial, patients were enrolled from 28 international sites. All patients treated with anthracyclines with another risk factor for heart failure were randomly allocated to GLS-guided (>12% relative reduction in GLS) or ejection fraction (EF)-guided (>10% absolute reduction of EF to <55%) CPT. The primary end point was the change in 3-dimensional (3D) EF (ΔEF) from baseline to 3 years., Results: Among 331 patients enrolled, 255 (77%, age 54 ± 12 years, 95% women) completed 3-year follow-up (123 in the EF-guided group and 132 in the GLS-guided group). Most had breast cancer (n = 236; 93%), and anthracycline followed by trastuzumab was the most common chemotherapy regimen (84%). Although 67 (26%) had hypertension and 32 (13%) had diabetes mellitus, left ventricular function was normal at baseline (EF: 59% ± 6%, GLS: 20.7% ± 2.3%). CPT was administered in 18 patients (14.6%) in the EF-guided group and 41 (31%) in the GLS-guided group (P = 0.03). Most patients showed recovery in EF and GLS after chemotherapy; 3-year ΔEF was -0.03% ± 7.9% in the EF-guided group and -0.02% ± 6.5% in the GLS-guided (P = 0.99) group; respective 3-year EFs were 58% ± 6% and 59% ± 5% (P = 0.06). At 3 years, 17 patients (5%) had cancer therapeutics-related cardiac dysfunction (11 in the EF-guided group and 6 in the GLS guided group; P = 0.16); 1 patient in each group was admitted for heart failure., Conclusions: Among patients taking potentially cardiotoxic chemotherapy for cancer, the 3-year data showed improvement of LV dysfunction compared with 1 year, with no difference in ΔEF between GLS- and EF-guided CPT. (Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes [SUCCOUR]; ACTRN12614000341628)., Competing Interests: Funding Support and Author Disclosures This study was supported in part by a project grant (1119955) from the National Health and Medical Research Council, Canberra, Australia, and an unrestricted grant from General Electric Healthcare, Horten, Norway. At the CHU de Québec site, the study was funded by the Fondation du CHU de Québec. Dr Marwick is supported by an investigator grant (2008129) from the National Health and Medical Research Council, Canberra, Australia. Dr Thavendiranathan is supported by a Canadian Institutes of Health Research New Investigator Award (147814), an Ontario Early Research Award, and a Canada Research Chair in Cardio-oncology. Dr K. Negishi is supported by a fellowship (award reference no. 101868) from the National Heart Foundation of Australia. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

9. Late diagnosis of a congenitally corrected transposition of the great arteries discovered at pacemaker implantation in a patient previously diagnosed with dextrocardia and situs solitus.

Author

Vasiliu A, Seldrum S, Dupont M, Dormal F, Blommaert D, and De Roy L

Abstract

Congenitally corrected transposition of the great arteries (CCTGA) should not be missed in patients with dextrocardia and situs solitus. We report a case of a 56-year-old man with late diagnosis of CCTGA after ventricular lead replacement. Free LV wall pacing may be favorable in these patients so to prevent deterioration of the systemic RV function.

Published
2018
Full Text
View/download PDF

10. Prognostic significance of LGE by CMR in aortic stenosis patients undergoing valve replacement.

Author

Barone-Rochette G, Piérard S, De Meester de Ravenstein C, Seldrum S, Melchior J, Maes F, Pouleur AC, Vancraeynest D, Pasquet A, Vanoverschelde JL, and Gerber BL

Subjects
Aged, Aortic Valve Stenosis mortality, Aortic Valve Stenosis surgery, Belgium epidemiology, Cause of Death trends, Contrast Media, Coronary Angiography, Echocardiography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Preoperative Period, Prognosis, Prospective Studies, Reproducibility of Results, Severity of Illness Index, Survival Rate trends, Aortic Valve Stenosis diagnosis, Cardiac Catheterization, Gadolinium DTPA, Heart Valve Prosthesis Implantation methods, Image Enhancement methods, Magnetic Resonance Imaging, Cine methods
Abstract

Background: Prior studies have shown that late gadolinium enhancement (LGE) by cardiac magnetic resonance (CMR) can detect focal fibrosis in aortic stenosis (AS), suggesting that it might predict higher mortality risk., Objectives: This study was conducted to evaluate whether LGE-CMR can predict post-operative survival in patients with severe AS undergoing aortic valve replacement (AVR)., Methods: We prospectively evaluated survival (all-cause and cardiovascular disease related) according to LGE-CMR status in 154 consecutive AS patients (96 men; mean age: 74 ± 6 years) without a history of myocardial infarction undergoing surgical AVR and in 40 AS patients undergoing transcatheter aortic valve replacement (TAVR)., Results: LGE was present in 29% of patients undergoing surgical AVR and in 50% undergoing TAVR. During a median follow-up of 2.9 years, 21 patients undergoing surgical AVR and 20 undergoing TAVR died. In surgical AVR, the presence of LGE predicted higher post-operative mortality (odds ratio: 10.9; 95% confidence interval [CI]: 1.2 to 100.0; p = 0.02) and worse all-cause survival (73% vs. 88%; p = 0.02 by log-rank test) and cardiovascular disease related survival (85% vs. 95%; p = 0.03 by log-rank test) on 5-year Kaplan-Meier estimates of survival after surgical AVR. Multivariate Cox analysis identified the presence of LGE (hazard ratio: 2.8; 95% CI: 1.3 to 6.9; p = 0.025) and New York Heart Association functional class III/IV (hazard ratio: 3.2; 95% CI: 1.1 to 8.1; p < 0.01) as the sole independent predictors of all-cause mortality after surgical AVR. The presence of LGE also predicted higher all-cause mortality (p = 0.05) and cardiovascular disease related mortality (p = 0.03) in the subgroup of patients without angiographic coronary artery disease (n = 110) and higher cardiovascular disease related mortality in 25 patients undergoing transfemoral TAVR., Conclusions: The presence of LGE indicating focal fibrosis or unrecognized infarct by CMR is an independent predictor of mortality in patients with AS undergoing AVR and could provide additional information in the pre-operative evaluation of risk in these patients., (Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Published
2014
Full Text
View/download PDF

11. Impact of preoperative symptoms on postoperative survival in severe aortic stenosis: implications for the timing of surgery.

Author

Piérard S, de Meester C, Seldrum S, Pasquet A, Gerber B, Vancraeynest D, Robert A, El Khoury G, Noirhomme P, and Vanoverschelde JL

Subjects
Aged, Female, Humans, Male, Postoperative Period, Preoperative Care, Prospective Studies, Severity of Illness Index, Survival Rate, Time Factors, Aortic Valve Stenosis mortality, Aortic Valve Stenosis surgery, Heart Valve Prosthesis Implantation
Abstract

Background: The impact of symptoms on the natural history of patients with severe aortic stenosis (SAS) has been well documented. By contrast, the implications of preoperative symptoms on postoperative outcomes remain poorly defined., Methods: The long-term survival of 812 patients greater than 65 years old with SAS undergoing bioprosthetic aortic valve replacement (AVR) was analyzed according to their preoperative symptoms., Results: Operative mortality was larger in New York Heart Association (NYHA) III-IV than in NYHA I-II patients (10% vs 6%, p = 0.036). Abrupt symptomatic deterioration from NYHA I to NYHA III-IV within the month preceding surgery was observed in 18% of NYHA III-IV patients and resulted in an increased operative mortality (17% vs 5% in NYHA I, p = 0.035). Long-term survival was also significantly worse in NYHA III-IV than in NYHA I-II patients (56% vs 72%, p = 0.002). Reduced long-term survival of NYHA III/IV patients was observed in subgroups with a left ventricular ejection fraction (LVEF) 0.50 or greater (58 vs. 74%, p = 0.008) and in those with a systolic pulmonary artery pressure (SPAP) less than 40 mm Hg (60% vs 74%, p = 0.014). By contrast, the presence of class III-IV symptoms did not influence outcome in patients with a LVEF less than 0.50 (51 vs. 55%, p = 0.34) or with a SPAP 40 mm Hg or greater (43% vs 48%, p = 0.78)., Conclusions: In patients with SAS, preoperative NYHA III-IV symptoms, particularly of recent onset, are independently associated with excess short- and long-term postoperative mortality. This was particularly evident in patients with normal LV function or pulmonary artery pressures. These findings plead in favor of an earlier surgical correction of SAS, before the onset of severe symptoms, especially in low-risk patients., (Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)

Published
2014
Full Text
View/download PDF

12. Aortic valve area, stroke volume, left ventricular hypertrophy, remodeling, and fibrosis in aortic stenosis assessed by cardiac magnetic resonance imaging: comparison between high and low gradient and normal and low flow aortic stenosis.

Author

Barone-Rochette G, Piérard S, Seldrum S, de Meester de Ravenstein C, Melchior J, Maes F, Pouleur AC, Vancraeynest D, Pasquet A, Vanoverschelde JL, and Gerber BL

Subjects
Aged, Aortic Valve diagnostic imaging, Aortic Valve physiopathology, Aortic Valve Stenosis complications, Aortic Valve Stenosis diagnosis, Echocardiography, Transesophageal, Female, Follow-Up Studies, Humans, Hypertrophy, Left Ventricular diagnosis, Hypertrophy, Left Ventricular etiology, Male, Retrospective Studies, Severity of Illness Index, Aortic Valve pathology, Aortic Valve Stenosis physiopathology, Blood Flow Velocity physiology, Hypertrophy, Left Ventricular physiopathology, Magnetic Resonance Imaging, Cine methods, Stroke Volume, Ventricular Remodeling
Abstract

Background: Recent works using echocardiography suggested that low gradient (LG), low flow (LF) aortic stenosis (AS) has more pronounced left ventricular (LV) concentric remodeling, smaller LV cavity size, and more interstitial fibrosis compared with high gradient (HG) normal flow (NF) AS. Therefore, we evaluated the accuracy of echocardiographic measurements and compared remodeling and fibrosis in different types of AS by cardiac magnetic resonance (CMR)., Methods and Results: A total of 128 patients (73±11 years of age; 75 men) with aortic valve area (AVA) <0.6 cm(2)/m(2) and ejection fraction >50% by echocardiography underwent CMR to measure planimetric AVA, phase-contrast indexed stroke volume, LV mass, and focal fibrosis. Using <40 mm Hg and indexed stroke volume <35 mL/m(2) by echocardiography as criteria for LG and LF, 69 (54%) patients were HG/NF, 28 (22%) HG/LF, 17 (13%) LG/NF, and 14 (11%) LG/LF AS. LV outflow tract area, indexed stroke volume, and AVA correlated well between echocardiography and CMR (r=0.7, 0.61, and 0.65, respectively; P<0.001 for all). By CMR, however, planimetric AVA was larger in LF/LG (0.54±0.08 cm(2)/m(2)) and LG/NF (0.61±0.08 cm(2)/m(2)) than in HG/LF (0.46±0.07 cm(2)/m(2); P<0.05) AS, and indexed LV mass was lower in LG/LF (75±12 g/m(2)) and LG/NF (81±18 g/m(2)) than in HG/LF (100±27 g/m(2); P<0.05) AS. All groups of AS had similar LV volumes, predominantly concentric hypertrophy remodeling, and similar amounts of focal fibrosis., Conclusions: CMR confirmed overall accuracy of echocardiographic classification of AS but demonstrated that LG/LF and LG/NF AS have larger AVA, less LV hypertrophy, and similar focal fibrosis compared with HG/LF AS. This challenges the view that LG/LF AS is a more advanced state of AS.

Published
2013
Full Text
View/download PDF

13. Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging.

Author

Seldrum S, Pierard S, Moniotte S, Vermeylen C, Vancraeynest D, Pasquet A, Vanoverschelde JL, and Gerber BL

Subjects
Adolescent, Adult, Analysis of Variance, Anemia blood, Asymptomatic Diseases, Belgium, Case-Control Studies, Child, Diastole, Female, Humans, Iron Chelating Agents therapeutic use, Iron Overload blood, Iron Overload drug therapy, Male, Predictive Value of Tests, Prospective Studies, Stroke Volume, Systole, Torsion, Mechanical, Ventricular Dysfunction, Left etiology, Ventricular Dysfunction, Left physiopathology, Young Adult, Anemia therapy, Iron Overload etiology, Magnetic Resonance Imaging, Cine, Transfusion Reaction, Ventricular Dysfunction, Left diagnosis, Ventricular Function, Left
Abstract

Background: It remains incompletely understood whether patients with transfusion related cardiac iron overload without signs of heart failure exhibit already subclinical alterations of systolic left ventricular (LV) dysfunction. Therefore we performed a comprehensive evaluation of systolic and diastolic cardiac function in such patients using tagged and phase-contrast CMR., Methods: 19 patients requiring regular blood transfusions for chronic anemia and 8 healthy volunteers were investigated using cine, tagged, and phase-contrast and T2* CMR. LV ejection fraction, peak filling rate, end-systolic global midventricular systolic Eulerian radial thickening and shortening strains as well as left ventricular rotation and twist, mitral E and A wave velocity, and tissue e' wave and E/e' wave velocity ratio, as well as isovolumic relaxation time and E wave deceleration time were computed and compared to cardiac T2*., Results: Patients without significant iron overload (T2* > 20 ms, n = 9) had similar parameters of systolic and diastolic function as normal controls, whereas patients with severe iron overload (T2* < 10 ms, n = 5), had significant reduction of LV ejection fraction (54 ± 2% vs. 62 ± 6% and 65 ± 6% respectively p < 0.05), of end-systolic radial thickening (+6 ± 4% vs. +11 ± 2 and +11 ± 4% respectively p < 0.05) and of rotational twist (1.6 ± 0.2 degrees vs. 3.0 ± 1.2 and 3.5 ± 0.7 degrees respectively, p < 0.05) than patients without iron overload (T2* > 20 ms) or normal controls. Patients with moderate iron overload (T2* 10-20 ms, n = 5), had preserved ejection fraction (59 ± 6%, p = NS vs. pts. with T2* > 20 ms and controls), but showed reduced maximal LV rotational twist (1.8 ± 0.4 degrees). The magnitude of reduction of LV twist (r = 0.64, p < 0.001), of LV ejection fraction (r = 0.44, p < 0.001), of peak radial thickening (r = 0.58, p < 0.001) and of systolic (r = 0.50, p < 0.05) and diastolic twist and untwist rate (r = -0.53, p < 0.001) in patients were directly correlated to the logarithm of cardiac T2*., Conclusion: Multiple transfused patients with normal ejection fraction and without heart failure have subclinical alterations of systolic and diastolic LV function in direct relation to the severity of cardiac iron overload. Among all parameters, left ventricular twist is affected earliest, and has the highest correlation to log (T2*), suggesting that this parameter might be used to follow systolic left ventricular function in patients with iron overload.

Published
2011
Full Text
View/download PDF

14. Incidence, determinants, and prognostic impact of operative refusal or denial in octogenarians with severe aortic stenosis.

Author

Piérard S, Seldrum S, de Meester C, Pasquet A, Gerber B, Vancraeynest D, El Khoury G, Noirhomme P, Robert A, and Vanoverschelde JL

Subjects
Age Factors, Aged, 80 and over, Female, Humans, Incidence, Male, Prognosis, Prospective Studies, Severity of Illness Index, Aortic Valve Stenosis surgery, Refusal to Treat
Abstract

Background: Aortic stenosis (AS) is a common valve disease in octogenarians. Previous studies have shown that aortic valve replacement (AVR) is frequently not performed in these patients. This study investigated the incidence, determinants, and prognostic impact of AVR refusal or denial in these patients., Methods: Between 2000 and 2007, 163 octogenarians (mean age, 84 ± 3 years) with severe AS and an indication for operation according to guidelines were prospectively included in an echocardiographic registry. Among these, 97 underwent AVR, and 66 were treated conservatively., Results: Logistic regression analysis identified older age, a lower transaortic pressure gradient, a larger aortic valve area, and the presence of diabetes as independent predictors of AVR refusal or denial. Patients who underwent AVR had a 30-day mortality of 9%. Overall 5-year survival was 66% in AVR patients vs 31% in those treated conservatively (log rank p < 0.001 vs AVR). After adjustment for the propensity score, patients undergoing AVR still had a better outcome than conservatively treated patients (hazard ratio, 0.56; 95% confidence interval, 0.29 to 0.91; p = 0.022). In addition to the therapeutic decision, Cox regression analysis also identified low body weight, New York Heart Association class III/IV, and the logistic European System for Cardiac Operative Risk Evaluation as independent predictors of outcome in the overall series., Conclusions: About 40% of octogenarians with severe AS and a definite indication for operation either refuse or are denied AVR. AVR refusal or denial has a profound impact on long-term prognosis, resulting in a twofold excess mortality, even after adjustment for the propensity score., (Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)

Published
2011
Full Text
View/download PDF

15. Images and case reports in interventional cardiology. Thrombotic aortic restenosis after transapical Sapien valve implantation.

Author

Kefer J, Astarci P, Renkin J, Glineur D, Pierard S, Seldrum S, and Vanoverschelde JL

Subjects
Aged, Animals, Aortic Valve diagnostic imaging, Aortic Valve pathology, Bioprosthesis adverse effects, Capsule Endoscopy, Cardiac Catheterization, Cattle, Coronary Angiography, Electrocardiography, Heart Valve Diseases diagnosis, Heart Valve Diseases pathology, Heart Valve Diseases physiopathology, Humans, Male, Myocardial Infarction, Platelet Aggregation Inhibitors therapeutic use, Thrombosis prevention & control, Ultrasonography, Warfarin therapeutic use, Aortic Valve surgery, Heart Valve Diseases therapy, Heart Valve Prosthesis Implantation, Postoperative Complications, Thrombosis etiology
Published
2010
Full Text
View/download PDF

16. Heparin-induced thrombocytopenia successfully treated with fondaparinux.

Author

Seldrum S, Lambert M, and Hainaut P

Subjects
Aged, Factor X, Follow-Up Studies, Fondaparinux, Humans, Male, Thrombocytopenia drug therapy, Anticoagulants therapeutic use, Fibrinolytic Agents adverse effects, Heparin adverse effects, Polysaccharides therapeutic use, Thrombocytopenia chemically induced
Abstract

We report the successful treatment of a patient with HIT-associated venous thrombosis by fondaparinux, a synthetic pentasaccharide. Although not yet approved for this indication, this new anticoagulant may be a useful alternative in the setting of HIT.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results